Kenneth Baker
General Practice · Norridgewock, MENPI 1407930068
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,588 of the $4,317 with a category attached, or 83.1%. It is spread thinly across 20 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,521, 3.7 times the $416 reported in 2019. Among general practice clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $29.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$593
- Axsome Therapeutics, Inc.$386
- Lilly USA, LLC$383
- Teva Pharmaceuticals USA, Inc.$338
- Vanda Pharmaceuticals Inc.$305
- GSK$292
- plus $2K from 14 others
What the payments were for
- Travel & lodging$2716%
- Food & beverage$3,58883%
- Education$45711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $593 |
| Axsome Therapeutics, Inc. | 4 | $386 |
| Lilly USA, LLC | 7 | $383 |
| Teva Pharmaceuticals USA, Inc. | 13 | $338 |
| Vanda Pharmaceuticals Inc. | 9 | $305 |
| GSK | 12 | $292 |
| Otsuka America Pharmaceutical, Inc. | 15 | $286 |
| Johnson & Johnson | 9 | $274 |
| E.r. Squibb & Sons, L.L.C. | 7 | $265 |
| Alkermes, Inc. | 9 | $259 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $244 |
| AbbVie | 7 | $165 |
| AstraZeneca | 6 | $122 |
| Neurocrine Biosciences, Inc. | 6 | $113 |
| Lundbeck LLC | 4 | $79 |
| Boehringer Ingelheim | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Braeburn Inc. | 2 | $41 |
| Novartis | 2 | $41 |
| Inspire Medical Systems, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,317 in reported general payments places this provider in the 95th percentile of 323 general practice providers in Maine.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 14 | $224 |
| Hydroxyzine Hcl | 11 | $212 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 13 | $101 |
Paid to pharmacies, not to this prescriber.
Other general practice in Norridgewock
- Andrea TalientoAugusta$167K
- Arjang DjamaliPortland$49K
- Ryan JeffreyBangor$7K
- Theodore MorganGorham$5K
- Robert McVetySpringvale$5K
- Kevin HadarYarmouth$4K
- Brian BoyntonYarmouth$3K
- Ryan SmithYork$3K
- Blair VannostrandFalmouth$3K
- Jason CurtisGorham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.